Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MWN-AI** Summary
On March 31, 2026, Fennec Pharmaceuticals Inc. (NASDAQ:FENC) announced the grant of incentive stock options (ISOs) to 24 new non-executive employees. This move, endorsed by the Compensation Committee of the Board of Directors on March 17, 2026, aligns with Nasdaq Listing Rule 5635(c)(4) and is intended to entice these new hires to join the company by providing them with equity in the form of stock options under its 2026 Equity Inducement Plan.
The approved grant allows the purchase of a total of 377,500 shares at an exercise price of $5.77 per share, equivalent to the closing price recorded on March 30, 2026. Each ISO carries a term of ten years, with vesting occurring in increments—one-third will vest one year post-grant, followed by monthly vesting over the subsequent two years. The options will trigger vesting contingent on the continued employment of each individual.
Fennec Pharmaceuticals is noteworthy for its focus on combating ototoxicity in patients undergoing cisplatin-based chemotherapy, primarily through its product, PEDMARK®. FDA approved in September 2022, and marketed in Europe as PEDMARQSI®, this drug aims to reduce the risk of hearing loss in cancer patients. Following its European launch by Norgine Pharmaceuticals in March 2024, Fennec's offerings have now become available in critical markets like the U.K. and Germany.
The company remains committed to addressing challenges associated with the commercialization of PEDMARK®/PEDMARQSI® and emphasizes ongoing regulatory and market potential. Cautioning against various risks that might impact future performance, Fennec anticipates navigating a dynamic environment as it continues to support its mission and employee initiatives. For more information, visit their website or follow on LinkedIn.
MWN-AI** Analysis
Fennec Pharmaceuticals' recent announcement regarding the grant of incentive stock options (ISOs) under Nasdaq Listing Rule 5635(c)(4) reflects the company’s strategic move to enhance its talent pool, which is critical for driving growth, particularly as it continues to expand its presence in the oncology market. The issuance of 377,500 stock options to 24 new employees is an encouraging indicator of Fennec's commitment to attracting skilled professionals essential for the commercialization of its lead product, PEDMARK®/PEDMARQSI®, aimed at mitigating cisplatin-induced ototoxicity in pediatric patients.
With an exercise price set at $5.77—directly reflecting its current market price—this maneuver not only aligns employee incentives with shareholder interests but also fosters a culture of ownership among new staff. The structured vesting schedule, which sees one-third of the options vesting after the first year followed by monthly vesting, ensures that employees are motivated to contribute to the company’s success over the long term.
Moreover, Fennec's recent regulatory approvals and licensing agreements signal its position as a significant player in the specialty pharmaceutical sector. The Orphan Drug Exclusivity in the U.S. and Pediatric Use Marketing Authorization in the EU provide a robust groundwork for development and could lead to considerable revenues as the company scales its commercialization efforts across various regions.
However, investors should remain cautious; while the growth potential is significant, Fennec must navigate a variety of risks including regulatory challenges, market access issues, and competitive pressures. As such, potential shareholders should perform comprehensive due diligence, monitor the company’s progress in clinical outcomes, and consider the broader market dynamics before making investment decisions. Overall, Fennec Pharmaceuticals presents an intriguing opportunity, but investors should weigh the potential benefits against inherent volatility in the biotech sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on March 17, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 377,500 of the Company’s common shares to 24 new non-executive employees of the Company with a grant date of March 31, 2026 under the Company’s 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of the Company, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4).
All ISOs have an exercise price of $5.77 per share, which is equal to the closing price of the Company’s common shares on The Nasdaq Capital Market on March 30, 2026, and a term of ten years from the date of grant. One-third of the shares underlying each ISO vest on the one-year anniversary of the grant date and continue to vest monthly thereafter over 24 months, subject to each employee’s continued employment with Company as of each such vesting date. The stock options are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an ISO agreement covering the grant.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK® received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI®.
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI® is now commercially available in the U.K. and Germany.
PEDMARK® has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI® has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection.
For more information, please visit www.fennecpharma.com and follow on LinkedIn.
Forward Looking Statements
Except for historical information described in this press release, all other statements are forward-looking. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about the Company’s business strategy, timeline and other goals, plans and prospects, including the Company’s commercialization plans respecting PEDMARK®/PEDMARQSI®, the market opportunity for and market impact of PEDMARK®/ PEDMARQSI®, its potential impact on patients and anticipated benefits associated with its use, future commercial and regulatory milestone and royalty payments from Norgine, and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including the risks and uncertainties that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company’s ability to obtain necessary capital when needed on acceptable terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2025. Fennec disclaims any obligation to update these forward-looking statements except as required by law.
For a more detailed discussion of related risk factors, please refer to the Company’s public filings available at www.sec.gov and www.sedar.com.
PEDMARK®, PEDMARQSI® and Fennec® are registered trademarks of Fennec Pharmaceuticals Inc.
©2025 Fennec Pharmaceuticals Inc. All rights reserved
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ**
How does Fennec Pharmaceuticals Inc ADHXD plan to leverage the recent stock option grants to attract and retain talent in a competitive pharmaceutical market?
What strategies is Fennec Pharmaceuticals Inc ADHXD implementing to ensure the successful commercialization of PEDMARK® following its recent approvals?
Can you provide insights into the potential market opportunities that Fennec Pharmaceuticals Inc ADHXD anticipates for PEDMARK® in targeted countries?
What risks does Fennec Pharmaceuticals Inc ADHXD foresee that may impact the anticipated benefits associated with the use of PEDMARK® in cancer treatment?
**MWN-AI FAQ is based on asking OpenAI questions about Fennec Pharmaceuticals Inc. (NASDAQ: FENC).
NASDAQ: FENC
FENC Trading
27.66% G/L:
$8.77 Last:
553,702 Volume:
$7.20 Open:
